Sickle Cell Anemia Drug Market Analysis - Global Industry Size, Share, Trends and Forecast, 2018 - 2026

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Forthcoming | Report ID : ARC571


Sickle cell disease is an inherited group of syndrome in which RBCs twist to sickle shape. A cluster of syndromes causes red blood cells (RBCs) to become distorted and break down. Some of the common symptoms of sickle cell disease are pain, infection and fatigue. Popular treatments for this disease include rarely a bone-marrow transplant, blood transfusions and medication.

Market Dynamics

Growing geriatric population in major economies and rising healthcare spending and demand for drug therapy in combination with blood transfusion and surgeries are driving the market growth. In addition, overall cost of sickle cell disease diagnosis is reduced, which in turn, is majorly influencing the market growth. However, adverse effects from sickle cell anemia such as intravenous catheter associated infections, liver in-toxicity and low hemoglobin are impeding the growth of this market. Government emphasis on spreading awareness about sickle cell anemia cure combined with augmentation of FDA approved drug accessibility are propelling the market expansion over the forecast period.

 Market Classification

The sickle cell anemia drug market is segmented on the basis of mode of delivery, end-user and geography. Based on mode of delivery, the market is classified into oral and injection. Based on type, the market is classified into hospital, clinic and others. Based on geography, market is divided into North America, Latin America, Europe, Asia-Pacific and Middle East & Africa (MEA).

Report Coverage


Sickle Cell Anemia Drug Market

Analysis Period

2015 – 2026

Historic Data

2015 – 2016

Base Year


Forecast Data

2018 – 2026

Market Stratification

Mode of Delivery, End-User, Geography

Regional Scope

North America, Europe, Asia-Pacific, Latin America, Middle East and Africa (MEA)

Report Coverage

Market Trends, Drivers, Restraints, Porter's Five Forces Analysis, Competitive Analysis,

Player Profiling, Value Chain Analysis


Market Participants

The market players in the sickle cell anemia drug market include Alnylam Pharmaceuticals, Inc., Pfizer Inc., Eli Lilly and Company, Baxter International Inc., Emmaus Life Sciences, Inc., Novartis AG, AstraZeneca Plc., Sangamo Therapeutics, Inc., bluebird bio, Inc., Global Blood Therapeutics Inc., Bristol-Myers Squibb Company, Acceleron Pharma, Inc. and Arena Pharmaceuticals, Inc. among others.

Market Segmentation

Market By Mode of Delivery

·         Oral

·         Injection

Market By End-Users

·         Hospital

·         Clinic

·         Others

Market By Geography

·         North America

o   US

o   Canada

o   Mexico

·         Europe

o   UK

o   Germany

o   France

o   Rest of Europe

·         Asia-Pacific

o   China

o   Japan

o   India

o   Australia

o   Rest of Asia-Pacific

·         Latin America

o   Brazil

o   Rest of Latin America

·         Middle East and Africa (MEA)

o   South Africa

o   Saudi Arabia

o   Rest of MEA

Cart Summary